Robert Winter MD
Dr. Robert Winter, a British doctor of general medicine, has gained notoriety throughout his home country and abroad as a researcher in the field of respiratory medicine. Winter, who began practicing medicine in 1977, received his training in London at three well-known institutions – Royal Brompton Hospital, University College Hospital, and Hammersmith Hospital.
Currently the medical director of the U.K.’s National Health Service (NHS) East of England division, Winter is also an associate lecturer at the University of Cambridge and serves as a consultant respiratory therapist at Cambridge, England’s Papworth Hospital, the largest cardiothoracic hospital in the United Kingdom. In addition, he is a consultant physician at Addenbrooke’s Hospital NHS Trust, also in Cambridge, and at Squire Cambridge Lea Hospital.
Professional accomplishments for Dr. Winter include his role as Chairman of the Emergency Care Steering Group at Addenbrooke’s Hospital, Chairman of the East of England Medical Directors’ Forum, and Chair of the Acute Care Clinical Pathways Group, an organization that addresses improvements in care for those with acute health concerns. Dr. Winter is also a member of the Addenbrooke’s Charitable Trust (ACT) Grants Committee and Research Advisory Committee, and Chairman of the hospital’s Professional Advisory Committee.
As an author, Winter has been published in a number of professional journals and has served as an Associate Editor for the journal Thorax and as a member of the editorial boards of the journals Medicine and Hospital Medicine.
As a researcher, Dr. Robert Winter focuses on adult respiratory medicine and is currently the lead investigator of a clinical trial concerning malignant mesothelioma, asbestos-caused cancer. Currently in Phase III, this trial centers on the study of video-assisted surgery, measuring its success in comparison to a procedure known as talc pleurodesis in treating patients with malignant mesothelioma. The two procedures are designed to reduce the amount of pleural effusion (fluid build-up) in patients with this rare form of thoracic cancer. Specifically, this clinical trial, entitled “Prospective Randomized Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cyto-reductive Pleurectomy Compared to Talc Pleurodesis in Patients with Suspected or Proven Malignant Mesothelioma”, will strive to measure whether the VAT will cause less damage to normal tissue than the more invasive pleurodesis procedure. The trial is ongoing until 2011.
Last modified: December 24, 2010.